The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood ...

The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma ...

AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...